Condition (MeSH)
Seminoma
ClinicalTrials.gov lists 62 trials for Seminoma or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
62 of the 62 trials are tagged with Seminoma itself; the rest are tagged with a narrower condition beneath it.
When did Seminoma trials start? (28)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 1 |
| 2024 | 3 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 1 |
| 2017 | 2 |
| 2016 | 2 |
Showing 10 of 28 earlier years.
No forecast is made for this condition: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 9 trials still running at the 2026-10-09 snapshot; registered median of 47 months across 25 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Seminoma trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 2 |
| Phase 2 | 26 |
| Phase 2/3 | 1 |
| Phase 3 | 14 |
| Not applicable | 9 |
| Observational | 7 |
How many Seminoma trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 13 |
| Active, not recruiting | 8 |
| Completed | 30 |
| Terminated | 4 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Seminoma trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 4 |
| National Cancer Institute (NCI) | 4 |
| Medical Research Council | 2 |
Which drugs are being tested for Seminoma? (7)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| (nab)-paclitaxel | 7 |
| Bleomycin | 4 |
| PEGFILGRASTIM | 3 |
| IPILIMUMAB | 2 |
| G-CSF | 2 |
Showing 5 of 7 drugs.
Interventions as named in the registry (8)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Cisplatin 1 | 11 |
| or carboplatin | 9 |
| Etoposid | 9 |
| Ifosfamid | 7 |
| Filgrastime (G-CSF) | 7 |
Showing 5 of 8 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Seminoma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Nausea | 16 | 2 |
| Vomiting | 15 | 2 |
| Neutrophils/granulocytes | 10 | 1 |
| Febrile Neutropenia | 9 | 1 |
| Hypotension | 6 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Seminoma? (34)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography in Early Metastatic Testicular Seminoma: Analysis From the SEMS Trial. | The Journal of urology | 2025 | Yes |
| Retroperitoneal Lymph Node Dissection in Clinical Stage IIA/B Metastatic Seminoma: Results of the COlogne Trial of Retroperitoneal Lymphadenectomy In Metastatic Seminoma (COTRIMS). | European urology oncology | 2024 | Yes |
| Primary Retroperitoneal Lymph Node Dissection for Seminoma Metastatic to the Retroperitoneum. | The Journal of urology | 2024 | Yes |
| Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023 | Yes |
| Evaluation of miR-371a-3p to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection. | Andrology | 2023 | Yes |
Showing 5 of 34 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.